Skip to main content

22-07-2020 | Rheumatology | News | Article

FDA approves guselkumab for psoriatic arthritis

Claire Barnard

medwireNews: The interleukin (IL)-23 inhibitor guselkumab has been approved for the treatment of psoriatic arthritis (PsA) in the USA.

Previously approved for plaque psoriasis, guselkumab may now be given to adults with active psoriatic arthritis (PsA), either as monotherapy or in combination with a conventional DMARD. The recommended dose is 100 mg given subcutaneously once every 8 weeks, following 100 mg loading doses at weeks 0 and 4.

“This is a new class of medications that is being developed for psoriatic arthritis.”

Click through to listen to lead investigator Philip Mease discussing the DISCOVER-2 trial results at the 2019 ACR/ARP Annual Meeting

The approval of guselkumab for PsA is based on the results of two phase 3 trials, DISCOVER-1 and DISCOVER-2, which demonstrated significantly greater ACR20 response rates with the IL-23 inhibitor versus placebo among PsA patients who were either biologic-naïve or had received prior treatment with up to two tumor necrosis factor inhibitors.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

See the research in context now

with trial summaries, expert opinion and congress coverage